Serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease isolates from children in mainland China—a systematic review
This study aimed to review and report the serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease (IPD) isolates, as this information is important for policy making since China has not adopted any pneumococcal vaccines in the national immunization schedule.
A systematic review of the published literature from January 2000 to December 2018 was performed to identify articles that describe the serotype and/or antimicrobial resistance patterns of IPD cases in children in mainland China. Analysis of the extracted data was performed with the Microsoft Excel spreadsheet program. The percentage of the serotypes was calculated by dividing the number of isolates for each serotype with the total number of isolates included in all the studies. The theoretical impact of the vaccine was estimated by calculating the percentage of isolates that exhibited the serotypes included in the vaccines. The prevalence of antimicrobial resistance was defined as the number of isolates that were resistant divided by the total number of isolates tested for resistance to the specific antimicrobial agent.
Forty-two articles were screened in the preliminary search, of which sixteen fulfilled inclusion criteria and were included in the final analysis. The predominant serotypes were 19A, 19F, 14, 23F, and 6B, and the estimated impact of PCV13 was 90.4%. The isolates exhibited a high frequency of resistance to cefuroxime, cefaclor, and erythromycin.
It is necessary for Chinese children to receive PCV13. Clinical workers should pay attention to the high frequency of resistance to antimicrobial agents.
KeywordsAntibiotic resistance Children Invasive pneumococcal disease Pneumococcal conjugate vaccine Serotype
- 1.World Health Organization (2019) WHO vaccine-preventable diseases: monitoring system. 2018 global summary. 2018; http://apps.who.int/immunization_monitoring/globalsummary. Accessed 01 April 2019
- 2.Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502PubMedCrossRefGoogle Scholar
- 4.Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging Infections Program Network (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201:32–41PubMedCrossRefGoogle Scholar
- 5.Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, Thomas A, Guevara RE, Motala T, Eason J, Barnes M, Petit S, Farley MM, McGee L, Jorgensen JH, Whitney CG (2016) Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 4:399–406CrossRefGoogle Scholar
- 7.Kambiré D, Soeters HM, Ouédraogo-Traoré R, Medah I, Sangaré L, Yaméogo I et al (2018) Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis-Burkina Faso, 2014-2015. J Inf Secur 76:270–279Google Scholar
- 12.Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM, Georgia Emerging Infections Program (2005) Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365:855–863PubMedCrossRefPubMedCentralGoogle Scholar
- 15.Schroeder MR, Chancey ST, Thomas S, Kuo WH, Satola SW, Farley MM, Stephens DS (2017) A population-based assessment of the impact of 7- and 13-valent pneumococcal conjugate vaccines on macrolide-resistant invasive pneumococcal disease: emergence and decline of Streptococcus pneumoniae serotype 19A (CC320) with dual macrolide resistance mechanisms. Clin Infect Dis 65:990–998PubMedPubMedCentralCrossRefGoogle Scholar
- 16.Zheng JS, Cao L, Guo SC, A KZ, Wang L, Yu WZ et al (2012) Survey on the immunization status of category B vaccine among children aged 1 to 2 years in China. Chin J Vaccine Immunization 18:233–237 (in Chinese)Google Scholar
- 17.Xue L, Yao K, Xie G, Zheng Y, Wang C, Shang Y, Wang H, Wan L, Liu L, Li C, Ji W, Xu X, Wang Y, Xu P, Liu Z, Yu S, Yang Y (2010) Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates that cause invasive disease among Chinese children. Clin Infect Dis 50:741–744PubMedCrossRefPubMedCentralGoogle Scholar
- 20.Zhou X, Liu J, Zhang Z, Liu Y, Wang Y, Liu Y (2016) Molecular characteristics of penicillin-binding protein 2b, 2x and 1a sequences in Streptococcus pneumoniae isolates causing invasive diseases among children in Northeast China. Eur J Clin Microbiol Infect Dis 35:633–645PubMedCrossRefGoogle Scholar
- 21.Xu F, Chi FL, Tan H, Liu XM, Cao T, Pan W et al (2012) Study on serotype distribution in 48 isolates of invasive Streptococcus pneumoniae with which children infected. Chin J Biochem Pharm 33:909–912 (in Chinese)Google Scholar
- 22.Lu C (2015) Investigation on serotype distribution of invasive pneumococcal disease isolates from children. Int J Lab Med 36:990–992 (in Chinese)Google Scholar
- 23.Zhou K, Xie GJ, Wang XW, Xu F, Yao KH (2015) Clinical characteristics of invasive pneumococcal disease and its serotype distribution. Chin J Nosocomiol 25:3392–3394 (in Chinese)Google Scholar
- 25.Shi W, Li J, Dong F, Qian S, Liu G, Xu B, Zhou L, Xu W, Meng Q, Wang Q, Shen K, Ma L, Yao K (2019) Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability. Expert Rev Vaccines 18:89–94PubMedCrossRefGoogle Scholar
- 28.Wang Q, Wu J, Liu J, Dong F, Yao KH, Shen KL et al (2016) Clinical features and outcomes of invasive pneumococcal disease in pediatric intensive care unit. Chin J Appl Clin Pediatr 31:1400–1404 (in Chinese)Google Scholar
- 30.Su M, Chang L, Zhou W, Mu LY, Kuang LH (2015) Clinical characteristics of children with meningitis caused by Streptococcus pneumoniae and antibiotic resistance of Streptococcus pneumoniae strains. Chin J Contemp Pediatr 17:706–709 (in Chinese)Google Scholar
- 31.Zou ZP (2015) Clinical features and antimicrobial resistance patterns of 102 pediatric cases with invasive pneumococcal disease. Shenzhen J Integr Tradit Chin W Med 25:188–190 (in Chinese)Google Scholar
- 32.Wang HM, Ma DL, Quan JL, Huang BX, Zhao RZ, Chen HY (2012) Drug-resistance of Streptococcus pneumoniae isolated from children. Chin J Infect Control 11(221–222):220 (in Chinese)Google Scholar
- 33.Zhang TD, Kong Q, Wang C, Qin HH, Zhang H (2014) Resistant mechanism of β-lactam antibiotic of invasive Streptococcus pneumoniae. Chin J Lab Med 37:748–752 (in Chinese)Google Scholar
- 34.Wang ML, Yan YD, Huang L, Zhu CH, Wang YQ, Chen ZR et al (2012) Clinical features and antimicrobial resistance of invasive pneumococcal disease in 38 children. Chin J Pract Pediatr 27:604–607 (in Chinese)Google Scholar
- 39.Jaiswal N, Singh M, Das RR, Jindal I, Agarwal A, Thumburu KK et al (2014) Distribution of serotypes, vaccine coverage, and antimicrobial susceptibility pattern of Streptococcus pneumoniae in children living in SAARC countries: asystematic review. PLoS One 9:e108617PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E (2015) Effect of the 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 15:535–543PubMedCrossRefGoogle Scholar
- 42.Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, Ndiaye M, Adeyemi O, Pathirana J, Olatunji Y, Abatan B, Muhammad BS, Fombah AE, Saha D, Plumb I, Akano A, Ebruke B, Ideh RC, Kuti B, Githua P, Olutunde E, Ofordile O, Green E, Usuf E, Badji H, Ikumapayi UNA, Manjang A, Salaudeen R, Nsekpong ED, Jarju S, Antonio M, Sambou S, Ceesay L, Lowe-Jallow Y, Jasseh M, Mulholland K, Knoll M, Levine OS, Howie SR, Adegbola RA, Greenwood BM, Corrah T (2016) Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 16:703–711PubMedPubMedCentralCrossRefGoogle Scholar
- 43.Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD, Harrison C, Bayley K, Watson M, Richmond P (2010) The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 50:1477–1486PubMedCrossRefGoogle Scholar
- 47.Clinical and Laboratory Standards Institute (CLSI) (2006) Performance standards for antimicrobial susceptibility testing; 20th informational supplement. Clinical and Laboratory Standards Institute, Wayne, pp M100–MS16Google Scholar
- 48.Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing; 20th informational supplement. Clinical and Laboratory Standards Institute, Wayne, pp M100–MS20Google Scholar
- 49.Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H et al (2012) Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother 56:1418–1426PubMedPubMedCentralCrossRefGoogle Scholar